From contested target to context-aware node: A three-layer regulatory code for interpreting FTO's oncogene-tumor suppressor paradox in cancer.

The fat mass and obesity-associated protein (FTO), the first identified N6-methyladenosine (m6A) RNA demethylase, has become both a leading candidate target in oncology and one of its most contested, behaving as an oncogene in some malignancies and as a tumor suppressor in others. Multiple inhibitor classes, FB23 derivatives, proteolysis-targeting chimera (PROTAC) degraders, repurposed entacapone, and tumor-targeted nanomedicines, have entered preclinical development, yet the clinical proposition remains unresolved because no framework currently predicts directionality or matches strategy to patient. We argue that this impasse reflects a missing conceptual frame, not missing molecules. Reading the field through a three-layer regulatory code offers a way to organize this paradox: an input code, in which K88 acetylation, USP7/USP30-mediated deubiquitination, oncometabolite 2-hydroxyglutarate, microbial CagA, lineage-specific transcription factors, and non-coding RNA scaffolds set FTO state; a processing code, in which subcellular localization, including localization to membraneless compartments, the YTHDF2 versus IGF2BP reader dichotomy, and a proposed non-catalytic scaffolding role select substrate fate; and an output code that maps onto metabolic rewiring, ferroptotic and pyroptotic decisions, immune sculpting, therapy resistance, and exosomal microenvironmental reach. The framework reorganizes therapeutic logic, direct inhibition, indirect modulation, rational combinations, or pharmacological activation, and reframes FTO from a contested target to a context-aware one whose translation depends on direction-aware precision oncology. Because the input, processing, and output layers are frequently drawn from different experimental systems, we present this code as an interpretive and hypothesis-generating scaffold rather than a validated predictive tool: it clarifies why FTO directionality varies and defines what must be measured to anticipate it, while prospective, within-model testing is still required before directionality can be assigned, or therapy matched, in an individual tumor.